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ABSTRACT
Introduction: Tuberculosis, a major killer disease in the community, was caused by Mycobacterium
tuberculosis. According to WHO (2006), pulmonary tuberculosis cases in Indonesia was third ranked in
the world. Prevalence of pulmonary tuberculosis in Eastern Indonesia was higher than in Java and Bali,
but the findings of positive smear was lowest. AFB discovery will be decreased because of the poor quality
and quantity of sputum. The useful of mucolitic ambroxol or hypertonic saline nebulizer induction will be
to increase quality and quantity of sputum smear.
Objectives: The aim of this study was to determine and to compare the effectiveness of ambroxol and
use a hypertonic saline induction on new suspected pulmonary tuberculosis patients to increase sputum
volume and to find AFB.
Methods: 76 new suspected pulmonary tuberculosis patients were divided into 2 groups with double-
blind and open-label simple random sampling RCT (Randomized Controlled Clinical Trial-Parallel design)
study.The sputum induction using ambroxol or 3% hypertonic saline solution.The primary and secondary
outcome were increasing sputum volume and finding AFB by Ziehl-Neelsen staining to calculate the AFB
count per 100 fields of view. Non parametric statistical analysis and percentage of success.
Results: All patients can produce sputum. Only one patient ambroxol group can’t produce it. The quality
and quantity of sputum hypertonic saline induction volume better than ambroxol. AFB finding increase
both groups, but no significant difference. AFB finding increase 26.47% (9/34) with ambroxol and 27.78%
(10/36) with hypertonic saline induction compared than previous negative smear.
Conclusions: Significant differences increase sputum volume hypertonic saline induction compared than
ambroxol. No significant difference AFB finding improvement hypertonic saline induction compared for
ambroxol. Finding AFB increase 26.47% with ambroxol and 27.78% with hypertonic saline induction
compared previous negative smear.
Keywords: Tuberculosis, Ambroxol, Nebulizer induction, Sputum volume, AFB
INTISARI
Pendahuluan: Penyakit tuberkulosis merupakan pembunuh utama dalam masyarakat, penyakit ini
disebabkan oleh Mycobacterium tuberculosis. Menurut WHO (2006) jumlah kasus TB paru di Indonesia
berada di peringkat ketiga di dunia. Prevalensi TB paru di Kawasan Timur Indonesia lebih tinggi
dibandingkan di Jawa dan Bali, tetapi temuan kasus BTA positif paling rendah. Oleh karena kualitas dan
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kuantitas dahak yang kurang baik, sehingga penemuan BTA berkurang. Perlunya upaya penemuan BTA
melalui pemberian ambroxol dan nebulizer salin hipertonis untuk meningkatkan kualitas dan kuantitas
dahak.
Tujuan: Mengetahui dan membandingkan hasil guna pemberian ambroxol dan nebulizer salin hipertonis
pada tersangka penderitaTB paru baru untuk meningkatkan volume dahak dan temuan BTA.
Metode: 76 orang tersangka TB paru baru yang dibagi dalam 2 kelompok dengan rancangan penelitian
RCT (Randomized Controlled Clinical Trial-Parallel design) secara simple random sampling metode double
blind dan open label. Induksi dahak menggunakan ambroxol dan nebulizer salin hipertonis (NaCl 3%).
Pemeriksaan meliputi pengukuran volume dahak dan menghitung angka BTA per 100 lapang pandang
dengan pewarnaan Ziehl-Neelsen.
Hasil: Adanya peningkatan volume dahak pada kelompok ambroxol (97,37%) dan nebulizer salin hipertonis
(100%), volume dahak kelompok nebulizer salin hipertonis lebih baik kualitas dan kuantitas dahak
dibandingkan kelompok ambroxol. Adanya peningkatan temuan BTA positif pada kelompok ambroxol
dan nebulizer salin hipertonis, tetapi tidak ada perbedaan bermakna kedua kelompok tersebut. Temuan
BTA meningkat 26,47% responden kelompok ambroxol dan 27,78% responden kelompok nebulizer salin
hipertonis dibandingkan BTA negatif sebelumnya.
Simpulan: Ada perbedaan bermakna berupa peningkatan volume dahak kelompok nebulizer salin
hipertonis dibandingkan ambroxol. Tidak ada perbedaan bermakna dalam hal peningkatan temuan BTA
kelompok nebulizer salin hipertonis dibandingkan ambroxol. Temuan BTA positif meningkat 26,47%
responden pada kelompok ambroxol dan 27,78% responden kelompok nebulizer salin hipertonis
dibandingkan BTA negatif sebelumnya.
Kata Kunci: Tuberkulosis, Ambroxol, Nebulizer salin hipertonis, Volume dahak, BTA
INDRODUCTION
Tuberculosis (TB) is a major killer disease in the
community, caused by Mycobacterium tuberculosis.
A third of the world’s population had been infected
and estimated are 8 million new cases and 3 million
deaths patients per year. One of ten patients
infected by Mycobacterium tuberculosiswill become
active TB1,2,3.
The Pulmonary TB cases in Indonesia
contributed 10% cases in the world1.Based on the
survey results to indicate the prevalence and
incidence rate differences of TB cases in three
regions variation of the estimated incidence of
smear positive TB cases in Java and Bali 64/100,000;
210/100,000 at Eastern Indonesia and 160/100,000
in Sumatra. The national prevalence decreased 4%
per year and the trend of slower decline in Sumatra
and Eastern Indonesia2.
The prevalence of PTB in Indonesia was 253
cases per 100,000 population per year and the
number of new smear positive incidence was 105
cases per 100,000 patients a year, while the death
rate due to TB was still high at 38 cases per 100,000
population in a year. TB average second ranked in
the outpatient clinic at the general hospital and the
first rank in the lung clinic and hospital. In the
outpatient unit of the general hospital, new cases
of TB accounted for 19% of all new respiratory
cases 2,4. The implementation of tuberculosis
eradication program, the tuberculosis diagnosis
was established if found AFB in microscopic smear
sputum. To find AFB in sputum examination for
tuberculosis was not easy1,5,6,7.
In 2007, the East Kalimantan province has CDR
(Case Detection Rate = number of patients finding
new smear positive TB) 29.7% and CNR (Case
Notification Rate) 62.5%. Samarinda has CNR
68.7% in 2006 and 55,9% in 2007, its to decrease
the discovery scope new smear positive patients.
The national target was 70%8. AFB discovery will
be decreased will the poor quality and quantity of
sputum. To find AFB in sputum smear microscopic
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of suspected tuberculosis was not easy. The
problem was the quality and quantity of sputum.
The ideal sputum for microscopic examination was
mucopurulen about 3-5 ml volume each collection.
It takes at least 5,000 AFB per milliliter to be seen
microscopically. If less of quality and quantity of
sputum, so to find the AFBlessalso7,9,10.
The quality and quantity sputum and sputum
physicochemical the structure affect the results
microscopic examination. Mucopolisaccharides
fibers and mucin acid, it can be difficult to catch
mycobacterial cells so make it difficult to
detect1,5,11. Microscopic examination of sputum
showed the poor quality sputum smear, so it’s need
education to health care workers and laboratory
personnel. The improving sputum collection need
continuous monitoring12.
Besides sputum physicochemical structure, the
acid mucopolisaccharides contains fibers make AFB
capture so difficult to be detected. The sputum
contained mucin can catch mycobacteria cells and
protects them from the decontamination
activities13. The expectorants can stimulate
secretions from the bronchi and tracheal spending,
to increase secretions or to break the acid
mucopolisaccharides fibers will be become more
watery sputum and AFB will be spread evenly14. The
useful of mucokinetic expectorant (ambroxol) was
expected to improve finding positive smear rate
higher compared than normal procedure.
Ambroxol as an expectorant mucokinetic helps
the secretion of the bronchi branch and increase
kinesis lowering the surface tension by stimulating
an effective spur surfactant transport of mucus
when coughing14,15. Ambroxol effects can be used
as mucokinetic the respiratory tract16, especially
chronic bronchitis patients17, which to dilute the
sputum patients have trouble removing it18.
To find a sputum smear examined using sputum
induction by inhalation hypertonic saline through a
nebulizer, particularly in patients with dry cough or
inadequate sputum volume/ scanty (less than 2
milliliters)19-24. Sputum induction was an effective
method inhalation to obtain adequate quantity of
sputum. Because of sputum dilution mucus from
steam hypertonic saline can be separated M.
tuberculosis from the trap21.
Hypertonic saline and ambroxol were the
expectorant mucokinetic type, which beneficial to
increase transport of mucus when coughing.
Ambroxol to increase coughing because the
stimulating effects of surfactant secretion.
Hypertonic saline to separate the DNA from the
infected mucus of bacteria, as to reduce the mucus
viscosity so it can increase sputum volume smear
and findings of previous negative patients15,19,21,22,25.
The aim of this study was to determine and to
compare between ambroxol or hypertonic saline
nebulizer induction for increase the sputum volume
and find AFB on suspects pulmonary tuberculosis
patients.
MATERIALS AND METHODS
The study design an open-label and double blind
simple random sampling RCTs (randomized
controlled Clinical Trial-Parallel design)26,27. The
independent variables were ambroxol and
hypertonic saline nebulizer induction and the
dependent variables were sputum volume and AFB
findings. Inclusion criteria were: suspecties new
pulmonary tuberculosis patients,who either having a
dry cough or scanty produce sputum, only produce
saliva or quantity sputum less than 2 ml and referral
cases that have been examined previously negative
smear, have existence of a written consent (informed
consent)and 18to 55 yearsageold. Exclusion criteria,
were:being intreatmentwithanti-tuberculosisdrugs,
history of severe respiratory illness, severe illness,
hypertension,pregnantorbreastfeeding,allergiesand
contraindications bromhexine or ambroxol and
nebulizer induction.
Materials and study tools were ambroxol 30
mg tablet and induction instrument uses ultrasonic
nebulizer hypertonic saline (NaCl 3% solution).
Sputum volume measurements using a measuring
cup and sputum smear stained Ziehl-Neelsen
method.Thedecontaminatenebulizerequipmentwas
washing,decontaminationandsterilization(bysoaking
in 2.4% glutaraldehyde for 10-12 hours at 25ºC
temperature).
Ambroxol HCl patients group agree to follow
the study (informed consent) will be given the 3
tablets ambroxol HCl 30 mg drug to be taken for 1
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day every 8 hours and notified via SMS (Short
Message Service).
Nebulizer induction group will be given
explanation about hypertonic saline (NaCl 3%
solution). A brief description of the procedure was
given to the patients. To avoid contamination,
patients gargled with normal solution to clear debris
from the mouth and oropharynx. All subjects asked
to inhale a mist of 3% hypertonic saline solution
(sterile) by ultrasonic nebulizer. Inhalation was
continued until an adequate sputum sample
(minimum 3 ml) or maximum period 30 minutes. The
nostrils were closed to prevent nasal inhalation. The
inhalation of hypertonic saline was interrupted
every 5 minutes, so the patient could expectorate
sputum. The implementation of induction nebulizer
will be monitoring the patient clinical state and
always O‚ tube and resuscitation equipment.
Ambroxol group performed 3 times sputum
collection, including: Sputum S1 was collected the
first time visiting. Sputum P was collected the
morning of the second day, immediately after
waking, before breakfast. And sputum S2 was
collected the second day after 6 hours submitted
sputum in the morning. The nebulizer induction
group 3 times sputum collection also. Sputum S1
was collected first visit and prior to the nebulizer.
Sputum P was collected conducted by hypertonic
saline nebulizer induction for 5-30 minutes. If the
patient could’t produce the sputum was be
hospitalized overnight at lung ward, was conducted
nebulizer 3 times a day. At the following morning
(before breakfast) was asked gargle normal saline
(NaCl 0.9% solution) to clean detruitus oral cavity.
Patients were asked to collect sputum to put in a
container. The sputum S2 was collected 6 hours
after sputum induction in the morning.
RESULT
1. General description of subjects
129 referral suspected pulmonary TB patients.
89 respondents who fulfilled the inclusion criteria
and 40 respondents are excluded because including
exclusion criteria. 76 patients agree and 13 patients
refused the study. After having history, physical
examination and chest x-ray. The patients will be
divided into 2 groups according computer program
that received ambroxol HCl drug was 38 patients
and received hypertonic saline induction was 38
patients. General description of study subjects are
presented in the following table:
Table 1. Distribution frequency age group subjects
p-value = 0.401, no significant difference between age of
treatment groups
No significant difference between age of the
treatment group.
Table 2. Distribution frequency gender subjects
p-value = 0.488, no significant gender differences to the treat-
ment group
No significant gender differences on the
treatment group.
2. Sputum volume
The initial sputum volume (S1) was differ from
the morning (P). Sputumvolume before giving
ambroxol (S1) differ than sputum volume after
administration of ambroxol sputum S2. Sputum
volume at the morning (P) differ than the sputum
S2 sputum. It appears the morning sputum volume
was the highest sputum volume produced.
The hypertonic saline nebulizer induction group
the initial sputum volume (S1) was different than
the morning sputum volume (P). Also sputum
volume (S1) was different than 6 hours after sputum
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collection time (S2). The morning sputum volume
(P) differ than collected after 6 hours post-induction
(S2). The highest produce sputum volume at the
nebulizer induction time or morning.
A. Comparison of sputum volume between
ambroxol and hypertonic saline nebulizer in-
duction group
Table 3. Comparison of sputum volume between
ambroxol and hypertonic saline nebulizer
inductiongroups
Description: S1 = the sputum volume at the initial time spu-
tum collection (before treatment), P =
sputum volume at the time of sputum collection time/ morn-
ing; S2 = sputum volume at the time of sputum collection 6
hours post-treatment/ morning
n = 38 respondents, the data in mean ± 2SE (ml)
*Wilcoxon Signed-Ranks Test significantly different between
ambroxol groups if p-value <0.05
**Wilcoxon Signed-Ranks Test was significantly different
between nebulizer induction groups if p value <0.05
***Mann-Whitney U-Test significantly different between
ambroxol and hypertonic saline nebulizer induction groups
if p-value<0,001
Both ambroxol and hypertonic saline nebulizer
induction group were significantly different from to
increasing sputum volume between initial sputum
volume(S1)than morningsputumvolume/time(P)or
the 6 hours post induction sputum volume (S2), so it
was concluded the sputum volume in each group
increased significantly.
B. The sputum volume test between ambroxol
and hypertonic saline nebulizer induction
groups no pair
Initial sputum volume S1 between ambroxol
and hypertonic saline nebulizer induction group. The
comparison of initial sputum volume (S1) between
ambroxol and hypertonic saline nebulizer induction
group were no significant difference in initial
sputum volume group.
Sputum volume P (morning) between mucolytic
ambroxol and induction hypertonic saline nebulizer
group. Comparison of morning sputum volume (P)
between ambroxol and hypertonic saline nebulizer
induction sputum group were significant
differences. Sputum volume after treatment (P)
showed the sputum volume hypertonic saline
nebulizer induction more than ambroxol group
(Table 3).
Sputum volume S2 between ambroxol and
hypertonic saline nebulizer induction group. It was
significant differences sputum volume (S2) between
ambroxol and hypertonic saline nebulizer induction
group, the sputum volume hypertonic saline
nebulizer induction group more than the ambroxol
group (Table 3).
C. Comparison of difference increase sputum
volume between ambroxol and hypertonic
saline nebulizer induction groups
The excess morning sputum volume (P) with
initial sputum volume (S1) are significant
differences between each other. Also it significant
differences between the sputum volume S2 than
initial sputum volume (S1). Similarly, sputum volume
S2 than morning sputum volume (P). It can be
concluded significant differences between sputum
volume ambroxol than hypertonic saline nebulizer
induction groups, nebulizer induction group was
higher than ambroxol group.





Δ Sputum volume P-S1
Δ Sputum volume S2-S1




*Mann-Whitney U Test was significantly dif-
ferent if p-value <0.05
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3. AFB Count
Some respondents of study before treatment
were found smear findings each group. At initial
sputum (S1) either 4 respondents ambroxol group
found positive sputum smear and hypertonic saline
nebulizer induction group 2 respondents. Finally, the
ambroxol group had 34 respondents and 36
respondents nebulizer induction group.
A. Comparative AFB count between
ambroxol group and hypertonic saline
nebulizer induction groups pairs
Both groups AFB count were increased signifi-
cantly especially the morning sputum (Table 5).
B. Comparative AFB count ambroxol and hyper-
tonic saline nebulizer induction groups un-
paired
No significant difference either initial collect-
ing sputum (S1) was compared than during in-
duction/morning (P) and 6 hours post-treat-
ment/morning sputum (Table 5). Initial sputum
(S1), both groups no found AFB (Table 5).
C. Comparison of AFB count increased differ-
ence between ambroxol and hypertonic sa-
line nebulizer induction groups
Table 5. Comparative pairs AFB count between ambroxol and hypertonic
saline nebulizer induction group
Collecting
time













Description: S1 = AFB count sputum smear at initial time (before treatment), P = AFB
count sputum smear at collection time/ morning; S2 = AFB count sputum smear at the
time of taking 6 hours posttreatment/morning
n = 34 ambroxol group respondents and n = 36 hypertonic saline nebulizer induction
group respondents, the data in the form of mean ± 2SE (AFB count per 100 fields of
view), Mann-Whitney U-Test was significantly different if p-value <0.05
*Wilcoxon Signed-Ranks Test significantly different S1 was compared than P and S2 if
p-value <0.05
**Wilcoxon Signed-Ranks Test significantly different S1 was compared than P and S2 if
p-value <0.05
The AFB count initial sputum smear (S1) and
the morning sputum (P) was no significant
difference each other. No significant difference in
the number of initial sputum smear (S1) than the 6
hours post treatment sputum smear (S2). Similarly,
the number of 6 hours post treatment sputum smear
(S2) to the number the morning sputum smear (P).
The concluded no significant AFB count difference
between ambroxol and hypertonic saline nebulizer
induction groups (Table 5).
The AFB count at morning sputum (P) and initial
sputum (S1) was no significant difference each
other. No significant difference in the excess AFB
count smear 6 hours post-treatment/morning
sputum (S2) than initial sputum smear (S1). Also it’s
similarly, the AFB count post-treatment sputum (S2)
than the morning sputum (P). It was concluded no
significant difference AFB count between ambroxol
than hypertonic saline nebulizer induction groups
(Table 6).
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Table 6. The difference AFB count smear between
ambroxol and nebulizer induction Groups
The difference p-value
Δ AFB count P-S1
Δ AFB count S2-S1




*Mann-Whitney U Test was significantly different if
p-value <0.05
4. The percentage of success increased sputum
volume
Only one person at ambroxol group can’t
exclude the sputum after ambroxol administration,
it was increased sputum volume 97.37% (37/38)
compared to before ambroxol treatment. All
patients (100%) at hypertonic saline nebulizer
induction group can increase sputum volume
compared to before treatment.
5. The percentage success rate in AFB on
ambroxol and hypertonic saline nebulizer in-
duction group negative initially sputum (S1).
Percentage success rate to find AFB was
different each group. Ambroxol group has 4 positive
smear initial sputum respondents. Thirty four
respondents whom initial sputum smear (S1) was
negative. After ambroxol administration were 9
respondents found both sputum smear positive in
the morning (P) and the second sputum (S2). It was
increasing 26.47% (9/34) smear positive findings
ambroxol group who previous negative smear.
Two respondents hypertonic saline nebulizer
induction group whom the initial sputum (S1) found
smear positive. Thirty four respondents initial
sputum smear (S1) were negative. After nebulizer
induction treatment were 10 respondents found
both positivesputum smear in the morning (P) and
6 hours after morning sputum (S2). The percentage
of success increased to finding positive smear was
27.78% (10/36) respondents hypertonic saline
nebulizer induction previous negative smear.
DISCUSSION
1. Comparison of sputum volume
A. Comparison of sputum volume between
ambroxol and hypertonic saline nebulizer in-
duction groups pair
The results of sputum collection in the
ambroxol group was increased sputum volume after
administration of ambroxol compared before drug
administration. Because to ambroxol was an
expectorants mucokinetic to facilitate or to
stimulate the disposal of bronchi and tracheal
secretions. The mucolytic physicochemical of
secretions change, especially lowering the viscosity
to be easily expelled by coughing14. Ambroxol has
to process acid mucopolisaccharides
pharmacokinetics so the fibers will be break down
mucus. It was increasing the production of
lysosomes and activates hydrolytic enzymes. It will
be stimulated serous gland cells causes the viscosity
of sputum secretions decrease, so it need process
time for metabolism and distribution to the target
organ15,18,28.
Meanwhile the hypertonic saline nebulizer
induction group to increase sputum volume
significantly, the results of sputum collection was
increasing sputum volume induction compared to
the sputum volume before treatment. The
hypertonic saline nebulizer induction to decrease
involvement of mucus in the airways. A hydrated
mucus in the airways would be more easily moved
by mucociliary and cough increased volume
secretion21,23,24,29.Hypertonic saline solution cause
bronchial irritation and stimulates the secretion of
bronchi. After 10-20 minutes nebulizer will be to
mobilize fluid production from lower respiratory
tract. Repeated coughing helps to move the product
into the trachea assisted with the expectorant19,30.
Both groups increased sputum volume,
especially the morning or sputum induction time of
the nebulizer. Although it was significant differences
each other groups, but comparison between groups
initial sputum volume (S1) between the two groups
was no significant.
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Each group shows that significant differences
after administration of ambroxol and after
induction to increase the sputum volume product.
The high difference significantly in sputum volume
was increased in the morning (P) and sputum S2 each
groups. The ambroxol group was increasing sputum
volume, but the increased sputum volume
hypertonic saline nebulizer induction group more
than it.
The ambroxol group to increase sputum volume
of 97.37% compared to before treatment and the
hypertonicsalinenebulizer inductiongrouptoincrease
all suspected pulmonarytuberculosis patients (100%)
compared to prior induction treatment.
B. Comparison of sputum volume between
ambroxol and hypertonic saline nebulizer in-
duction groups no pair
Comparison of initial sputum volume (S1)
between ambroxol and hypertonic saline nebulizer
induction groups was no significant difference. The
initial sputum volume (S1) in both groups did not
differ significantly. Preliminary data showed same
relatively, because it has been randomized.
Comparison of morning sputum volume (P)
between ambroxol and hypertonic saline nebulizer
induction group were significant differences.
Sputum volume after treatment showed hypertonic
saline nebulizer induction group more than
ambroxol group (Table 3). The hypertonic saline
nebulizer induction will be effect faster and more
immediately19, it was differ the effects of
expectorant mucolytic drugs must be through the
pharmacokinetic mechanism (absorption,
distribution, metabolism and excretion) so requires
a time14. Ambroxol has the effect of spur secretion
of fluid in conditions of moderate to strong
stimulated, to maintain viscosity and sputum
volume in the medium stimulated, because
ambroxol stimulates the secretion of ions Cl¯
through Naz / Kz /2Cl ¯ cotransporter at the basal
condition, while the under basal conditions
ambroxol will be stop the secretion of Cl¯ and
HCO3¯ and does not to affect to the anions
secretion31.
No significant differences between sputum
volume (S2) ambroxol and hypertonic saline
nebulizer induction group, which the sputum volume
nebulizer induction group more than ambroxol
group (Table 3).
The useful of hypertonic saline will be more
sputum volume production, because it cause
irritation to the mucosal bronchial and to stimulate
the secretion of bronchi. The putative mechanism
of action to improve mucociliary clearance and or
increase osmolarity fluid of respiratory tract, where
to increase vascular permeability mucosal bronchi,
and submucosal glands produce mucus spur. After
10-20 minutes nebulizer to mobilizes fluid
production from lower respiratory tract products
and induction effects of nebulizer will be decrease
4 hours later19,32.
According to Rogers25 and Rubin33 that
expectorant mucokinetics, like: ambroxol and
hypertonic saline to work through the sputum
transportation when coughing. The mechanism of
action alleged by kinesis mucus and coughing can
be removed mucus from lower respiratory tract.
â2-adrenoceptor agonist will be stimulate increase
airflow and ciliary beat, Cl¯/water secretion and
mucin, increasing the sputum volume and surfactant
reduces mucus adhesions to epithelium caused the
sputum airway easy to exit.
The inflammatory process due to bacterial
infection occur mucus hypersecretion, cilia
dysfunction and changes in the composition of
respiratory secretions. It contains inflammatory
cells, especially neutrophils. The presence of
neutrophils from the release of proinflammatory
mediators by epithelial airway damage. It caused
the DNA release and filamentous actin (F-actin) and
the cytoskeleton of DNA and F-actin copolymerize.
Mucin degradation in polymers, the release of DNA
and actin network. It causes to increase sputum
secretion and to decrease sputum viscosity, so
resulting in decreased adhesion to the airway
surface epithelium. It was caused sputum become
unsticky to adhesion the respiratory tract surface
and to cough cause sputum easily out include the
AFB contained25,34.
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2. Comparison of AFB finding
Ambroxol, as an expectorant to increase
volume and thin sputum, was making it easier for
spending sputum from branches of the terminal
bronchial. The sputum had contained acid
mucopolisaccharides fibers and mucin, could
complicate capture mycobacteria cells making it
difficult to detect1,5,11. Mucolytic expectorant will
be describe the bonding acid mucopolisaccharides
fibers so that sputum becomes more dilute and
reduced viscosity. To provide sputum release for
mycobacteria which it trapped by acid mucopoli-
saccharides and mucus that are easier to find14,15.
After ambroxol treatment led smear easy to find,
was reflected significant differences in the AFB
number of smear before giving ambroxol compared
after administration of ambroxol primarily on
sputum smear rates in the morning or at any rate
of sputum smear (S2). Because it possible coincided
with the melting of the lesions or tubercles next day,
especially at the morning2,7,9. Mucolytic has the
pharmacokinetic effects, are significant differences
in the increase in sputum volume. It is will be to
increase sputum volume but did not always
correlate with increased AFB count of smear. The
peak of mucolytic ambroxol levels (Tmax) <1.6
hours in plasma despite having a long half-life of
10 hours, the effect will be decrease pharmaco-
kinetic through oxidative metabolism was triggered
by cytochrome P450 CYP3A4 so mucolytic effect
to decline followed a decrease of decomposition
of acid mucopolisaccharides also followed by a
decrease mucus bronchi biodegradable fibers that
led to the discovery of smear rates declined as
well14,25 .
Ambroxol effects through coughing
effectiveness will spur surfactants secretion. The
mechanism of action through the ability
mucokinetic, mucociliary activity, stimulate the
production of surfactants, anti-inflammatory and
antioxidative action alleged role in the ability to
stimulate the secretion of bronchi15.
Comparative between the initial sputum smear
(S1) is different from the time of the induction rate
of sputum smear hypertonic saline nebulizer in the
morning (P). The mechanism of mucolytic was to
decrease involvement mucus in the airways. The
mechanism of nebulizer induction in osmolarity
through the saline solution on epithelium airway will
be inhaled and followed by the increase in water
containing airway mucus. A hydrated mucus in the
airways increased volume secretion would be more
easily moved by mucociliary and cough21,23,24,29,35.
Hypertonic saline can also to separate the DNA
from the infected mucin in the mucus, through a
reduction in mucus viscosity. Hypertonic solution
cause bronchial irritation and stimulates secretion
of bronchi. After 10-20 minutes nebulizer occurs
that mobilizes fluid product from lower respiratory
tract. Repeated coughing can helps to move the
product into the trachea, including AFB that trapped
in mucopolisaccharides acids that can be helped
with expectorant, so the discovery of a larger AFB
smear19,30. Nebulizer induction was an effective
method as the initiation to discovery of suspects
pulmonary tuberculosis who can’t remove sputum
or previous negative smear examination results.
The chest x-ray on suspected pulmonary tuber-
culosis patients who have cavitation and infiltrates
will be to increase 19.9% the findings AFB sputum
through the hypertonic saline induction36.
The hypertonic saline nebulizer induction group
smear rates prior to the nebulizer (S1) is different
from the AFB count smear after induction (NaCl 3%
solution) during or initial morning (P). While AFB
count prior to the nebulizer (S1) was similar
collected after 6 hours AFB sputum collection time/
morning S2. Similarly, the AFB count smear during
induction nebulizer or morning (P) was not different
from the AFB count smear was collected after 6
hours post-nebulizer induction using hypertonic
saline S2.
This study shows the AFB findings in the initial
sputum (S1) was not different than the AFB count
smear after 6 hours nebulizer (S2). Similarly, AFB
count findings at the time of induction nebulizer (P)
than AFB count after 6 hours nebulizer (S2). The
majority of respondents had performed induction
nebulizer only one time with a nebulizer induction
will be to increasing AFB count smear sputum,
although there were no significant differences in
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the AFB count smear rates after nebulizer 6 hours
(S2). After 10-20 minutes fluid production will be
mobilizing product of lower respiratory tract.
Repeated coughing will be helps moving the product
into the trachea30,37.
It has relationship between to find leukocytes
and neutrophils increased with the AFB discovery
smear in pulmonary tuberculosis patients diagnosed
after bronchoscopy are accompanied fever41. The
AFB count smear nebulizer or morning (P) was not
different from AFB count smear was collected after
6 hours postnebulizer induction use hypertonic
saline (S2). Similarly, the AFB count smear prior to
the nebulizer (S1) was similar collected after 6 hours
AFB count sputum collection time/morning S2.
The mechanism action nebulizer induction
made solution will become droplets. Smaller
droplets will be deposited into the peripheral lung.
Therefore hypertonic saline fluids used for
deposition through a process of osmosis to
interstitial fluid to the lower respiratory tract.
Hypertonic saline solution will cause irritation to
spur secretion of the bronchi. After 10-20 minutes
nebulizer bronchi secretion will be mobilize
material from lower respiratory tract, including AFB.
Repeated coughing will help transfer the material
into the trachea functions as an expectorant42.
Some studies have reported that repeated sputum
induction after initial induction between 8-24 hours
would cause an increase neutrophils count in the
second sample, so it isn’t recommended sputum
induction with a nebulizer repeated38,39. The 48
hours interval time between nebulizer induction will
be to provide a significant number of normal cells
in individuals, so many studyers to advise a
minimum time limit for repeat nebulizer induced
sputum isn’t more than 2 days to avoid the effects
of “carry-over” of induction40. Sputum induction
results to contain a high concentration of liquid
phase components such as eosinophil cationic
proteins (ECP), mucin glycoprotein and albumin than
in BAL. It was indicates the existence from
respiratory secretions than space alveolar43.
The sputum smear, which found bacteria, is a
mucin protein-rich complex medium and a DNA
degradation product. The nebulizer induction
produce sputum contains many mediators
compared than bronchoalveolar lavage. Finding AFB
smear rates between the two groups are significant
differences. The ambroxol group to find smear rate
more survive either the morning sputum (P) and
post-administration drugs, because ambroxol has
half-life long enough and high volume distribution15.
Comparative sputum volume between
ambroxol and hypertonic saline nebulizer induction
groups no pair Comparison of initial sputum volume
(S1) between ambroxol and hypertonic saline
nebulizer induction groups were no significant
difference, because it was randomized.
Comparison of morning sputum volume (P)
between ambroxol and hypertonic saline nebulizer
induction groups were significant differences. The
sputum volume hypertonic saline nebulizer
induction group more than the ambroxol group
(Table 5).
Because hypertonic saline nebulizer induction
effect was faster and more immediately19, was
different the effects of expectorant mucolytic drugs
that through the pharmacokinetic mechanism
(absorption, distribution, metabolism and
excretion) so requires a certain time14. Surface
ambroxol molecules and its metabolites were not
found in electron-deficient regions, so many
compounds can’t react with glutathione and DNA
nucleobase. The existence of electron-rich region
on the surface of the lower respiratory tract and
induction effects will be decline after 4 hours19,32.
The comparison AFB count between ambroxol
and hypertonic saline nebulizer induction nebulizer
groups
The AFB count sputum smear S1 ambroxol and
hypertonic saline nebulizer induction groups. The
statistical test of AFB count initial sputum/before
treatment (S1) ambroxol and hypertonic saline
nebulizer induction groups are no significant
difference (p-value = 0.639), it were relatively equal
smear both groups because it was randomized. The
AFB finding on sputum smear before treatment (S1)
because more careful examination and appropriate
procedures for sputum examination in the hospital
compared to previous primary care. According to
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Sakundarno12 the quality of sputum was necessary
to find the AFB of smear, so training needed to
obtain high quality sputum for laboratory
examination. If poor quality and quantity of
sputum, to find AFB also lacking. According to ATS9,
Siddiqi et al.10 and WHO7, the quality of sputum
and microscopic preparations, either increase the
sensitivity up to 80% compared than smear culture
method.
The AFB finding morning sputum (P) smear
between ambroxol and hypertonic saline nebulizer
induction groups did not differ significantly.
Although was a significant increase in sputum
volume at hypertonic saline nebulizer induction
compared than ambroxol group, but this was not
followed always increase the AFB findings smear.
The mechanism of bronchial mucosal stimulation
to irritation can increase sputum volume but not
always increase the AFB count findings, because the
AFB need acid mucopolisaccharides decomposition.
The previous study (Williams et al45. Brown et al46;
Uskul et al47) was showed the induced sputum,
gastric washings and bronchoalveolar lavage did
not differ findings smear rates despite increased
sputum volume induction but hypertonic saline
nebulizer induction cheaper and more effective
than other procedures.
The AFB findings post-treatment sputum smear
(S2) inbothgroupswasnotsignificant, althoughthere
weresignificantdifferencesinsputumvolumebetween
each groups. It was to increase sputum volume
hypertonicsalinenebulizer inductiongroupcompared
than ambroxol group. It can be explained that the
nebulizer induction to increase sputum volume, but
wasn’t always followed by increasing AFB findings.
Because it has other processes can influence AFB
findings, such as acid mucopolisaccharides bond
decomposition.
The ambroxol and nebulizer induction groups
had significant differences to AFB finding initial
sputum compared than the morning sputum/during
sputum induction and 6 hours after morning
sputum. Statistical analysis showed that the data
was no significant difference increased BTA findings
both ambroxol and nebulizer induction groups.
Unpaired statistical analysis showed no significant
difference either groups.
3. The percentage of success increased sputum
volume
Ambroxol group was increasing sputum volume
97.37% compared to before giving drugs, while the
hypertonic saline nebulizer induction group to
increase entirely (100%) to all suspected pulmonary
tuberculosis patients sputum volume increase
compared to before hypertonic saline nebulizer
induction. It was not different to other study.
According to Gupta and Garg19 the success of 97%
from the quality of less than 2 ml previous sputum.
4. The percentage of success increased AFB
count
Ambroxol group has to increase AFB findings
to smear of 26.47% compared to prior treatment,
while hypertonic saline nebulizer induction group
will be increase smear findings of 27.78% compared
to before induction previous negative smear. It was
not different previous studies at 19-42%, like: 19%
(Anderson et al48.); 25% (Parry et al23.; Merrick et
al49.); 33.9% (Li et al20.); 34% (Conde et al50.); 42%
(Hartung et al51.); 38% (Gupta and Garg19) and 19.9%
(Garcia et al36.). Mechanism of action of saline as
mucolytic to reduction involving the mucus
respiratory tract. The fluid osmolarity will be
dilution during hypertonic saline inhalation. Because
the hydrated mucus respiratory will be facilitate
movement by mucociliary clearance was
accompanied by increased sputum volume.
Hypertonic saline solution will be separating DNA
mucus from the infected mucus smear, causes to
decrease viscosity mucus25.
Statisticalanalysisshowedsignificantdifferences
in AFB smear findings in each group like increased





The expectorant ambroxol or saline induction
hypertonic nebulizer will be to increase sputum
volume and AFB count findings on suspected
pulmonary tuberculosis patients. It was significant
differences between the provision to increase
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sputum volume between ambroxol and hypertonic
saline nebulizer induction, where nebulizer induction
more than ambroxol. No significant difference to
increase AFB findings expectorant between
ambroxol and hypertonic saline nebulizer induction.
97.37% ambroxol patients group and all patients
(100%) hypertonic saline nebulizer induction group
can increase quality and quantity sputum compare
previous treatment. 26.47% patients ambroxol
group were found positive smear and 27.78%
patients hypertonic saline nebulizer induction group
compared than previous negative smear.
SUGGESTION
The suspects pulmonary tuberculosis patients,
who can’t remove sputum or less than 2 milliliters
advise to take ambroxol first, if failed to proceed
hypertonic saline nebulizer induction. The continu-
ed study development with a higher standard smear
findings (ie. culture smear).
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